Douglas B Fox
Overview
Explore the profile of Douglas B Fox including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
910
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fox D, Ebright R, Hong X, Russell H, Guo H, LaSalle T, et al.
NPJ Precis Oncol
. 2023 Mar;
7(1):25.
PMID: 36864091
Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs) and functional...
2.
Sundaresan T, Dubash T, Zheng Z, Bardia A, Wittner B, Aceto N, et al.
Breast Cancer Res Treat
. 2021 Jun;
188(1):43-52.
PMID: 34101078
Purpose: Therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive breast cancer is limited by the acquisition of ligand-independent ESR1 mutations, which confer treatment resistance to aromatase inhibitors (AIs)....
3.
Walens A, Lin J, Damrauer J, McKinney B, Lupo R, Newcomb R, et al.
Nat Commun
. 2020 Oct;
11(1):5017.
PMID: 33024122
The survival and recurrence of residual tumor cells following therapy constitutes one of the biggest obstacles to obtaining cures in breast cancer, but it remains unclear how the clonal composition...
4.
Fox D, Garcia N, McKinney B, Lupo R, Noteware L, Newcomb R, et al.
Nat Metab
. 2020 Jul;
2(4):318-334.
PMID: 32691018
The survival and recurrence of dormant tumour cells following therapy is a leading cause of death in cancer patients. The metabolic properties of these cells are likely distinct from those...
5.
Madonna M, Fox D, Crouch B, Lee J, Zhu C, Martinez A, et al.
Mol Cancer Res
. 2019 Mar;
17(7):1545-1555.
PMID: 30902832
With the large number of women diagnosed and treated for breast cancer each year, the importance of studying recurrence has become evident due to most deaths from breast cancer resulting...
6.
Mabe N, Fox D, Lupo R, Decker A, Phelps S, Thompson J, et al.
J Clin Invest
. 2018 Aug;
128(10):4413-4428.
PMID: 30148456
Tumor relapse is the leading cause of death in breast cancer, largely due to the fact that recurrent tumors are frequently resistant to chemotherapy. We previously reported that downregulation of...
7.
McDonnell E, Crown S, Fox D, Kitir B, Ilkayeva O, Olsen C, et al.
Cell Rep
. 2016 Nov;
17(6):1463-1472.
PMID: 27806287
Cells integrate nutrient sensing and metabolism to coordinate proper cellular responses to a particular nutrient source. For example, glucose drives a gene expression program characterized by activating genes involved in...
8.
Sundaresan T, Sequist L, Heymach J, Riely G, Janne P, Koch W, et al.
Clin Cancer Res
. 2015 Oct;
22(5):1103-10.
PMID: 26446944
Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-mutant non-small cell lung cancers (NSCLC) as they become resistant to selective tyrosine kinase inhibitors (TKI). As third-generation...
9.
Miyamoto D, Zheng Y, Wittner B, Lee R, Zhu H, Broderick K, et al.
Science
. 2015 Sep;
349(6254):1351-6.
PMID: 26383955
Prostate cancer is initially responsive to androgen deprivation, but the effectiveness of androgen receptor (AR) inhibitors in recurrent disease is variable. Biopsy of bone metastases is challenging; hence, sampling circulating...